Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Obstructive sleep apnea and Parkinson's disease: characteristics and associated factors.

Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, Almeida CMO, Fernandes RMF, Tumas V, Eckeli AL.

Arq Neuropsiquiatr. 2019 Sep 23;77(9):609-616. doi: 10.1590/0004-282X20190098. eCollection 2019.

2.

Chronic Insomnia in Patients With Parkinson Disease: Which Associated Factors Are Relevant?

Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, de Almeida CMO, Fernandes RMF, Tumas V, Eckeli AL.

J Geriatr Psychiatry Neurol. 2019 Jun 18:891988719856687. doi: 10.1177/0891988719856687. [Epub ahead of print]

PMID:
31213118
3.

Time Perception of an Artwork's Manipulation Is Distorted by Patients With Parkinson's Disease.

Motta MR, Tumas V, Bueno JLO.

Front Integr Neurosci. 2019 Mar 8;13:6. doi: 10.3389/fnint.2019.00006. eCollection 2019.

4.

The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia.

Novaretti N, Cunha ALN, Bezerra TC, Pena Pereira MA, de Oliveira DS, Macruz Brito MMC, Pimentel AV, Brozinga TR, Foss MP, Tumas V.

Tremor Other Hyperkinet Mov (N Y). 2019 Feb 4;9:596. doi: 10.7916/fhnv-v355. eCollection 2019.

5.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi: 10.1007/s00406-019-00982-6. Epub 2019 Jan 31. Review.

PMID:
30706171
6.

Epidemiological and clinical aspects of a sample of Brazilian patients with primary dystonia and the impact of the new classification on their clinical evaluation.

Bezerra TC, Novaretti N, Cunha ALN, Pereira MAP, Oliveira DS, Brito MCM, Pimentel ÂV, Tumas V.

Arq Neuropsiquiatr. 2018 Dec;76(12):821-826. doi: 10.1590/0004-282X20180138.

7.

Global cognitive performance is associated with sleep efficiency measured by polysomnography in patients with Parkinson's disease.

Sobreira EST, Sobreira-Neto MA, Pena-Pereira MA, Chagas MHN, Fernandes RMF, Eckeli AL, Tumas V.

Psychiatry Clin Neurosci. 2019 May;73(5):248-253. doi: 10.1111/pcn.12819. Epub 2019 Feb 21.

PMID:
30636105
8.

Factors related to excessive sleepiness in patients with Parkinson's disease.

Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, de Almeida CMO, Fernandes RMF, Tumas V, Eckeli AL.

Neurol Res. 2019 Mar;41(3):227-233. doi: 10.1080/01616412.2018.1548746. Epub 2018 Nov 21.

PMID:
30462589
9.

Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases.

Marchioni C, de Souza ID, Acquaro VR Junior, de Souza Crippa JA, Tumas V, Queiroz MEC.

Anal Chim Acta. 2018 Dec 31;1044:12-28. doi: 10.1016/j.aca.2018.06.016. Epub 2018 Jun 9. Review.

PMID:
30442393
10.

Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review.

de Almeida CMO, Pachito DV, Sobreira-Neto MA, Tumas V, Eckeli AL.

J Neurol Sci. 2018 Oct 15;393:63-68. doi: 10.1016/j.jns.2018.08.008. Epub 2018 Aug 10. Review.

PMID:
30118919
11.

Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.

Bariotto-Dos-Santos K, Padovan-Neto FE, Bortolanza M, Dos-Santos-Pereira M, Raisman-Vozari R, Tumas V, Del Bel E.

Eur J Neurosci. 2019 Mar;49(6):869-882. doi: 10.1111/ejn.14079. Epub 2018 Sep 25.

PMID:
30022547
12.

Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients.

Tavares de Andrade HM, Cintra VP, de Albuquerque M, Piccinin CC, Bonadia LC, Duarte Couteiro RE, Sabino de Oliveira D, Claudino R, Magno Gonçalves MV, Dourado MET Jr, de Souza LC, Teixeira AL, de Godoy Rousseff Prado L, Tumas V, Bulle Oliveira AS, Nucci A, Lopes-Cendes I, Marques W Jr, França MC Jr.

Neurobiol Aging. 2018 Sep;69:292.e15-292.e18. doi: 10.1016/j.neurobiolaging.2018.04.020. Epub 2018 May 8.

PMID:
29934271
13.

Huntington's disease-like disorders in Latin America and the Caribbean.

Walker RH, Gatto EM, Bustamante ML, Bernal-Pacheco O, Cardoso F, Castilhos RM, Chana-Cuevas P, Cornejo-Olivas M, Estrada-Bellmann I, Jardim LB, López-Castellanos R, López-Contreras R, Maia DP, Mazzetti P, Miranda M, Rodríguez-Violante M, Teive H, Tumas V.

Parkinsonism Relat Disord. 2018 Aug;53:10-20. doi: 10.1016/j.parkreldis.2018.05.021. Epub 2018 May 21. Review.

PMID:
29853295
14.

The frequency of the C9orf72 expansion in a Brazilian population.

Cintra VP, Bonadia LC, Andrade HMT, de Albuquerque M, Eusébio MF, de Oliveira DS, Claudino R, Gonçalves MVM, Teixeira AL Jr, de Godoy Rousseff Prado L, de Souza LC, Dourado MET Jr, Oliveira ASB, Tumas V, França MC Jr, Marques W Jr.

Neurobiol Aging. 2018 Jun;66:179.e1-179.e4. doi: 10.1016/j.neurobiolaging.2018.01.007. Epub 2018 Jan 31.

PMID:
29449030
15.

Erratum: Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Cornejo-Olivas M, Torres L, Velit-Salazar MR, Inca-Martinez M, Mazzetti P, Cosentino C, Micheli F, Perandones C, Dieguez E, Raggio V, Tumas V, Borges V, Ferraz HB, Rieder CRM, Shumacher-Schuh A, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Chang-Castello J, Andreé-Munoz B, Waldherr S, Yearout D, Zabetian CP, Mata IF.

NPJ Parkinsons Dis. 2018 Jan 19;4:3. doi: 10.1038/s41531-017-0025-1. eCollection 2018.

16.

High Frequency of Sleep Disorders in Parkinson's Disease and Its Relationship with Quality of Life.

Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, Fernandes RMF, Tumas V, Eckeli AL.

Eur Neurol. 2017;78(5-6):330-337. doi: 10.1159/000481939. Epub 2017 Oct 30.

PMID:
29084403
17.

Recalling feature bindings differentiates Alzheimer's disease from frontotemporal dementia.

Cecchini MA, Yassuda MS, Bahia VS, de Souza LC, Guimarães HC, Caramelli P, Carthery-Goulart MT, Patrocínio F, Foss MP, Tumas V, Lima-Silva TB, Brucki SMD, Nitrini R, Della Sala S, Parra MA.

J Neurol. 2017 Oct;264(10):2162-2169. doi: 10.1007/s00415-017-8614-9. Epub 2017 Sep 11.

18.

Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Cornejo-Olivas M, Torres L, Velit-Salazar MR, Inca-Martinez M, Mazzetti P, Cosentino C, Micheli F, Perandones C, Dieguez E, Raggio V, Tumas V, Borges V, Ferraz HB, Rieder CRM, Shumacher-Schuh A, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Chang-Castello J, Andreé-Munoz B, Waldherr S, Yearout D, Zabetian CP, Mata IF.

NPJ Parkinsons Dis. 2017 Jun 2;3:19. doi: 10.1038/s41531-017-0020-6. eCollection 2017. Erratum in: NPJ Parkinsons Dis. 2018 Jan 19;4:3.

19.

Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.

Santos-Lobato BL, Borges V, Ferraz HB, Mata IF, Zabetian CP, Tumas V.

Nitric Oxide. 2018 Apr 1;74:86-90. doi: 10.1016/j.niox.2017.06.004. Epub 2017 Jun 8.

PMID:
28602747
20.

A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples.

Marchioni C, de Souza ID, Grecco CF, Crippa JA, Tumas V, Queiroz MEC.

Anal Bioanal Chem. 2017 May;409(14):3587-3596. doi: 10.1007/s00216-017-0300-3. Epub 2017 Mar 23.

PMID:
28337517
21.

Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings.

Chagas MHN, Tumas V, Pena-Pereira MA, Machado-de-Sousa JP, Carlos Dos Santos A, Sanches RF, Hallak JEC, Crippa JAS.

J Psychiatr Res. 2017 Jul;90:40-45. doi: 10.1016/j.jpsychires.2017.02.010. Epub 2017 Feb 13.

PMID:
28222355
22.

Huntington's Disease like 2 presenting with isolated Parkinsonism.

Vasconcellos LFR, Macêdo PJOM, Franck JB, Tumas V, Marques Júnior W, Spitz M.

J Neurol Sci. 2017 Feb 15;373:105-106. doi: 10.1016/j.jns.2016.11.050. Epub 2016 Nov 23. No abstract available.

PMID:
28131164
23.

Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.

Rojas GVE, Ricz H, Tumas V, Rodrigues GR, Toscano P, Aguiar-Ricz L.

J Voice. 2017 May;31(3):391.e7-391.e18. doi: 10.1016/j.jvoice.2016.09.029. Epub 2016 Nov 17.

PMID:
27866691
24.

Bipolar disorder, a precursor of Parkinson's disease?

Novaretti TMS, Novaretti N, Tumas V.

Dement Neuropsychol. 2016 Oct-Dec;10(4):361-364. doi: 10.1590/s1980-5764-2016dn1004018.

25.

Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease.

Tumas V, Borges V, Ballalai-Ferraz H, Zabetian CP, Mata IF, Brito MMC, Foss MP, Novaretti N, Santos-Lobato BL.

Dement Neuropsychol. 2016 Oct-Dec;10(4):333-338. doi: 10.1590/s1980-5764-2016dn1004013.

26.

Cluster analysis of cognitive performance in a sample of patients with Parkinson's disease.

Souza CP, Oliveira GN, Foss MP, Tumas V.

Dement Neuropsychol. 2016 Oct-Dec;10(4):315-319. doi: 10.1590/s1980-5764-2016dn1004010.

27.

Cognitive dysfunction and dementia in movement disorders.

Barbosa ER, Teive HAG, Tumas V.

Dement Neuropsychol. 2016 Oct-Dec;10(4):259-260. doi: 10.1590/s1980-5764-2016dn1004001. No abstract available.

28.

Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.

Hawthorne GH, Bernuci MP, Bortolanza M, Tumas V, Issy AC, Del-Bel E.

Neurotox Res. 2016 Nov;30(4):715-729. Epub 2016 Aug 31. Review.

PMID:
27581037
29.

Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s.

Santos-Lobato BL, Tumas V.

Arq Neuropsiquiatr. 2016 Aug;74(8):687-9. doi: 10.1590/0004-282X20160095.

30.

Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases.

Batista-Filho MM, Kandratavicius L, Nunes EA, Tumas V, Colli BO, Hallak JE, Maia-de-Oliveira JP, Evora PR.

CNS Neurol Disord Drug Targets. 2016;15(8):976-986. Review.

PMID:
27450870
31.

Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

Chien HF, Rosso ALZ, Santos ASD, Rieder CRM, Maia DP, Silva DJD, Andrade MDC, Coletta MVD, Costa MDDLD, Allam N, Prado RCPD, Borges V, Tumas V, Horta WG.

eNeurologicalSci. 2016 Jul 19;5:11-14. doi: 10.1016/j.ensci.2016.07.001. eCollection 2016 Dec.

32.

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Ferreira JJ, Mahlknecht P, Tumas V, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2016 Oct;31(10):1466-1478. doi: 10.1002/mds.26675. Review.

PMID:
27296904
33.

Cytoarchitecture of nitrergic neurons in the human striatum and subthalamic nucleus.

Santos-Lobato BL, Del-Bel E, Pittella JE, Tumas V.

Brain Res Bull. 2016 Jun;124:129-35. doi: 10.1016/j.brainresbull.2016.04.003. Epub 2016 Apr 6.

PMID:
27060610
34.

The interlocking finger test in patients with Parkinson's disease and healthy subjects.

Souza CP, Oliveira GN, Foss MP, Tumas V.

J Clin Neurosci. 2016 Jul;29:145-8. doi: 10.1016/j.jocn.2015.09.026. Epub 2016 Mar 5.

PMID:
26960261
35.

Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia.

Barbosa PM, Rodrigues GR, de Oliveira DS, de Souza CP, Tumas V.

Clin Neuropharmacol. 2015 Nov-Dec;38(6):221-6. doi: 10.1097/WNF.0000000000000107.

PMID:
26536017
36.

Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.

Sobreira E, Pena-Pereira MA, Eckeli AL, Sobreira-Neto MA, Chagas MH, Foss MP, Cholerton B, Zabetian CP, Mata IF, Tumas V.

Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.

37.

Effects of aging on nitrergic neurons in human striatum and subthalamic nucleus.

Santos-Lobato BL, Del-Bel EA, Pittella JE, Tumas V.

Arq Neuropsiquiatr. 2015 Sep;73(9):779-83. doi: 10.1590/0004-282X20150097.

38.

An analysis of the cognitive items of the movement disorders society checklist for the diagnosis of dementia in patients with Parkinson's disease.

Oliveira GN, Souza CP, Foss MP, Tumas V.

Parkinsonism Relat Disord. 2015 Oct;21(10):1260-3. doi: 10.1016/j.parkreldis.2015.08.005. Epub 2015 Aug 11.

PMID:
26289825
39.

[Cannabinoids in neurology--Brazilian Academy of Neurology].

Brucki SM, Frota NA, Schestatsky P, Souza AH, Carvalho VN, Manreza ML, Mendes MF, Comini-Frota E, Vasconcelos C, Tumas V, Ferraz HB, Barbosa E, Jurno ME.

Arq Neuropsiquiatr. 2015 Apr;73(4):371-4. doi: 10.1590/0004-282X20150041. Epub 2015 Apr 1. Portuguese.

40.

Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.

Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, Salmon CE.

Magn Reson Imaging. 2015 Jun;33(5):559-65. doi: 10.1016/j.mri.2015.02.021. Epub 2015 Feb 24.

PMID:
25721997
41.

Excessive fragmentary myoclonus in patients with Parkinson's disease: prevalence and clinico-polysomnographic profile.

Sobreira-Neto MA, Pena-Pereira MA, Sobreira ES, Chagas MH, Tumas V, Fernandes RM, Eckeli AL.

Sleep Breath. 2015 Sep;19(3):997-1002. doi: 10.1007/s11325-014-1098-2. Epub 2015 Jan 8.

PMID:
25566939
42.

Nitric oxide, a new player in L-DOPA-induced dyskinesia?

Del-Bel E, Padovan-Neto FE, Bortolanza M, Tumas V, Aguiar AS Jr, Raisman-Vozari R, Prediger RD.

Front Biosci (Elite Ed). 2015 Jan 1;7:168-92. Review.

PMID:
25553372
43.

Mutational screening of 320 Brazilian patients with autosomal dominant spinocerebellar ataxia.

Cintra VP, Lourenço CM, Marques SE, de Oliveira LM, Tumas V, Marques W Jr.

J Neurol Sci. 2014 Dec 15;347(1-2):375-9. doi: 10.1016/j.jns.2014.10.036. Epub 2014 Oct 31.

PMID:
25466696
44.

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA.

J Psychopharmacol. 2014 Nov;28(11):1088-98. doi: 10.1177/0269881114550355. Epub 2014 Sep 18.

PMID:
25237116
45.

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.

Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.

J Clin Pharm Ther. 2014 Oct;39(5):564-6. doi: 10.1111/jcpt.12179. Epub 2014 May 21.

PMID:
24845114
46.

Validation of the Brazilian version of the Clinical Gait and Balance Scale and comparison with the Berg Balance Scale.

Baggio JA, Curtarelli Mde B, Rodrigues GR, Tumas V.

Arq Neuropsiquiatr. 2013 Sep;71(9A):621-6. doi: 10.1590/0004-282X20130107.

47.

Mattis dementia rating scale (DRS) normative data for the brazilian middle-age and elderly populations.

Foss MP, de Carvalho VA, Machado TH, Dos Reis GC, Tumas V, Caramelli P, Nitrini R, Porto CS.

Dement Neuropsychol. 2013 Oct-Dec;7(4):374-379. doi: 10.1590/S1980-57642013DN74000004.

48.

Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control.

Stewart T, Sui YT, Gonzalez-Cuyar LF, Wong DT, Akin DM, Tumas V, Aasly J, Ashmore E, Aro P, Ginghina C, Korff A, Zabetian CP, Leverenz JB, Shi M, Zhang J.

Neurobiol Aging. 2014 Feb;35(2):418-20. doi: 10.1016/j.neurobiolaging.2013.08.008. Epub 2013 Sep 13.

49.

Neuroimaging of depression in Parkinson's disease: a review.

Chagas MH, Linares IM, Garcia GJ, Hallak JE, Tumas V, Crippa JA.

Int Psychogeriatr. 2013 Dec;25(12):1953-61. doi: 10.1017/S1041610213001427. Epub 2013 Sep 2. Review.

PMID:
23992107
50.

New perspectives in nuclear neurology for the evaluation of Parkinson's disease.

Benadiba M, Luurtsema G, Tumas V, Buchpigel CA, Busatto GF.

J Parkinsons Dis. 2013 Jan 1;3(3):301-23. doi: 10.3233/JPD-130207. Review.

PMID:
23981822

Supplemental Content

Support Center